by Importantly, we provide some mechanistic insight into these findings. end points that were either significantly higher (10 proteins) or significantly lower (9 proteins) in the AOM + DSS + AG group compared with the AOM-alone (control) group. Overall, these results suggest that AG keeps the colon environment in metabolic equilibrium when mice are treated with AOM + DSS and gives insight into the mechanisms by which AG protects from colon cancer associated with colitis. == Introduction == Numerous studies have established a link between colitis and colon cancer (13). The relative risk of colorectal cancer development in ulcerative colitis (UC) patients is 10-fold greater than in the general population (4) and this risk increases with duration of the colitis (2). The histopathogenesis of UC-associated colorectal cancer involves a stepwise progression from inflamed and hyperplastic epithelia, to flat dysplasia, to adenocarcinoma (5). Cancer appears to be derived through a multistep process, involving sequential alterations at the molecular and tissue levels. However, the specific molecular events have not been fully described, and little is known what occurs during colitis in mice. We have shown previously that American Ginseng (AG), a putative non-toxic antioxidant can both prevent and treat dextran sulfate sodium (DSS) and oxazolone-induced colitis in mice (6). As a continuation of these studies, here we describe an ability of AG to inhibit azoxymethane (AOM)/DSS-induced colitis-driven colon cancer. We also explore the mechanistic insight by demonstrating some molecular changes in precancerous colon epithelial cells from mice treated with AOM + DSS versus AOM/DSS + AG. == Materials and methods == == American ginseng == The details and characteristics of AG have been described previously by our group in detail (6). An identical lot of AG has been used for these studies. Briefly, AG extract was purchased from the National Indoximod (NLG-8189) Research Council of Canada. This extract was derived from roots of AG cultivated by Chai-Na-Ta Farms Ltd (Kamloops, British Columbia, Canada) and processed by Canadian Phytopharmaceuticals Corporation Indoximod (NLG-8189) (Richmond, British Columbia, Canada). Following grinding to pass 80 mesh, 35 kg of the root material was extracted with aqueous ethanol (75% ethanol and Indoximod (NLG-8189) 25% water) in a recirculating filter extraction system for 4 h at a temperature of 60C under vacuum. The ratio of solvent to root was 8:1 (vol:wt). After extraction, the filtrate was partially driedinvacuoto yield a concentrated extract. Maltodextrin (2.8 kg) Rabbit polyclonal to YY2.The YY1 transcription factor, also known as NF-E1 (human) and Delta or UCRBP (mouse) is ofinterest due to its diverse effects on a wide variety of target genes. YY1 is broadly expressed in awide range of cell types and contains four C-terminal zinc finger motifs of the Cys-Cys-His-Histype and an unusual set of structural motifs at its N-terminal. It binds to downstream elements inseveral vertebrate ribosomal protein genes, where it apparently acts positively to stimulatetranscription and can act either negatively or positively in the context of the immunoglobulin k 3enhancer and immunoglobulin heavy-chain E1 site as well as the P5 promoter of theadeno-associated virus. It thus appears that YY1 is a bifunctional protein, capable of functioning asan activator in some transcriptional control elements and a repressor in others. YY2, a ubiquitouslyexpressed homologue of YY1, can bind to and regulate some promoters known to be controlled byYY1. YY2 contains both transcriptional repression and activation functions, but its exact functionsare still unknown (40% of final weight) was then blended as a support and the resultant slurry was spray dried to yield 7 kg of free flowing powder. Analysis by Canadian Phytopharmaceuticals Corporation by high-performance liquid chromatographyultraviolet against pure standards determined the total ginsenoside content (as the sum of: Rg1, Re, Rb1, Rc, Rb2 and Rd) of the finished material to be 10.1% (wt/wt) and confirmed by high-performance liquid chromatographymass spectrometry at the National Research Council, Canada. The final, powder form of AG extract also contained 2% additional ginsenosides (made up of F11, Ro, isomers of Rd and traces of malonyl ginsenosides) and 40% of maltodextrin derived from hydrolyzed cornstarch. The remaining 48% of the powder was made up of ginseng root-derived polysaccharides/ligosaccharides and proteins and up to 5% of moisture. The lot utilized in this study was screened and found to comply with standards set (e.g. NSF/ANSI 173-03) for heavy metals and contaminants in dietary supplements and is periodically tested by National Research Council of Canada, Institute for National Measurement Standards to confirm stability of the ginsenoside content. It should be noted here that regular AIN-93M chow fed to mice contains 12.5% maltodextrin. The addition of 75 p.p.m. AG in the chow equates to 30 mg/kg final concentration of maltodextrin added to 12.5% already in the chow. Therefore, there is 12.5% maltodextrin in the AIN-93M chow and 12.5003% of maltodextrin in the AIN-93M chow supplemented with 75 p.p.m. AG extract. == AOM/DSS-induced Indoximod (NLG-8189) colon cancer model == We followed a modified protocol outlined recently by the Wirtzet al.(7).Supplementary Table 1(available atCarcinogenesisOnline) outlines the treatment groups.
